Group 1 - Cocrystal Pharma, Inc. will present a company overview and clinical progress update at NobleCon 21 on December 3, 2025 [1] - The conference will take place at the Executive Education Complex of Florida Atlantic University in Boca Raton, Florida [1] - Interested investors can attend the conference at a discounted rate using the code COCPNOBLECON [2] Group 2 - Cocrystal Pharma is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [4] - The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs [4] Group 3 - Noble Capital Markets is a research-driven investment bank that has supported small and microcap companies since 1984 [3] - The firm provides institutional-quality equity research, merchant and investment banking, and order execution services [3] - Noble launched Channelchek in 2018, an investor community dedicated to public small and micro-cap companies, offering free institutional-quality research [3]

Core Insights - Sunshine Biopharma Inc. has developed a new series of orally active, non-covalent protease inhibitors with dose-dependent antiviral activity against SARS Coronavirus (SARS-CoV-2) [1] - The research was conducted in collaboration with the University of Arizona [1] Company Developments - The new protease inhibitors are aimed at providing life-saving medicines in therapeutic areas including oncology and antivirals [1] - The ongoing collaboration with the University of Arizona highlights the company's commitment to advancing its research capabilities [1]